Plasma-lyte for intravenous fluid maintenance, replacement or resuscitation as an alternative to other intravenous fluids in paediatric patients: A systematic review

Edwards ED¹, Mason BW²

INTRODUCTION
Plasma-Lyte is a licensed isotonic fluid that can be used as an intravenous (IV) fluid for maintenance, replacement or resuscitation in children and infants. It can be used as an alternative to IV fluids containing 0.45% or 0.9% Sodium Chloride (NaCl), with or without potassium or glucose 5%. Using Plasma-Lyte in place of currently utilised intravenous fluid has the potential for cost savings.

The early clinical trials in adults comparing 0.9% saline with Plasma-Lyte had small sample sizes and reported short term biochemical outcomes [1]. Although 0.9% saline was associated with decreased serum pH, elevated serum chloride levels and decreased bicarbonate levels in these studies, no significant difference was found between groups in renal function [1,2]. A subsequent large multicentre double-blind cluster randomised controlled trial comparing 0.9% saline with Plasma-Lyte in acutely ill adults found no significant difference between group in rates of acute kidney injury, acute kidney injury requiring renal replacement therapy, and 90 day mortality [3]. A large cluster-randomized, multiple-crossover trial conducted in critically ill adults, found that the use of balanced crystalloids (including Plasma-Lyte) for intravenous fluid administration resulted in a lower rate of acute kidney injury and use of renal replacement therapy, and 90 day mortality [3].

The characteristics of intravenous fluids employed in the paediatric population are described by Langer et al. [6]. Plasma-Lyte contains Na+ 140 mEq L–1, Cl– 98 mEq L–1, Acetate 27 mEq L–1, Gluconate 23 mEq L–1, and a Tonicity of 296 mOsm L–1. In contrast 0.9% NaCl contains Na+ 154 mEq L–1, Cl– 154 mEq L–1, Acetate 0 mEq L–1, Gluconate 0 mEq L–1, and a Tonicity of 308 mOsm L–1. The composition of intravenous fluids determines their effect on plasma acid-base and electrolyte equilibrium [6,7]. The term "balanced solutions" is used to define solutions, such as Plasma-Lyte, that have electrolyte concentrations close to those of plasma [8]. The chloride concentration of Plasma-Lyte is not only closer to that of plasma than 0.9% NaCl but also nearer to plasma than other balanced solutions. Chloride-restrictive fluid administration has been found to be associated with a lower incidence of acute kidney injury and use of renal replacement therapy in [6]. It is therefore plausible that the use of Plasma-Lyte in children will have better outcomes than alternative IV fluids.

RESULTS
Seven articles, which reported 5 studies, met the inclusion criteria. A single high quality peer reviewed randomised controlled trial (RCT) demonstrated that in comparison with 0.9% NaCl for rehydration in children with gastroenteritis, Plasma-Lyte was well tolerated and led to more rapid improvement in serum bicarbonate and dehydration score. The remaining studies provided low grade evidence of better or equivalent biochemical or blood gas outcomes when Plasma-Lyte was used as an alternative to 0.9 % NaCl.

LIMITATIONS
Small number published studies, only two RCTs, only 1 peer reviewed publication.

CONCLUSIONS
Plasma-Lyte is a licensed isotonic fluid that can be used for intravenous fluid maintenance, replacement and resuscitation in children and infants. It conforms to the 2015 The National Institute for Health and Care Excellence (NICE) guideline on intravenous fluid therapy in children and young people in hospital. The limited published evidence available suggests that in children Plasma-Lyte is equivalent to or possible superior in some situations to alternative intravenous fluids.

KEY WORDS
Plasma-lyte; Sodium chloride; Acute kidney injury; Gastroenteritis; Hyperkalaemia

METHODS
Search strategy
The electronic database MEDLINE and EMBASE were searched using the free text terms with wildcard truncation "Plasmalyte*" and "Plasma-lyte*". Searches were undertaken on 2nd December 2018. The searches from the two databases were combined to remove duplicate publications.

Study selection
The abstracts of all publications were screened independently by two authors to properly cite and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com
Edwards, et al.

(EDE and BW) to identify all papers that potentially met the following criteria:

- The publication reported a controlled trial, quasi experimental, cohort, case-control study, or systematic review; and,
- The patients studied were paediatric (less than 18 years of age); and,
- The study compared Plasma-Lyte with an alternative intravenous fluid for maintenance, replacement or resuscitation; and,
- The study reported any outcome.

The full texts of potentially relevant publications were obtained and reviewed to determine if they met the above inclusion criteria. The findings of included publications were summarised. The methodological quality of randomised controlled trials was assessed using the Jadad five point scale [9].

RESULTS

Study selection

The search of electronic databases identified 222 publications from MEDLINE and 495 publications from EMBASE, with 530 unique publications from the combined searches. Screening of abstracts of these 530 publications identified 46 publications that potentially met the inclusion criteria. Review of the full text of these 46 publications identified 7 papers that met the inclusion criteria (Figure 1). The 39 papers were excluded for one or more of the following reasons: the publication did not report a controlled trial, quasi experimental, cohort, case-control study, or systematic review (6 papers); the patients studied were not paediatric (31 papers); the study did not compare Plasma-Lyte with an alternative intravenous fluid (11 papers); the fluids were not used for maintenance, replacement or resuscitation (7 papers); and, the study did not report any outcome (7 papers).

Only 1 randomised controlled trial (RCT) was described in full to allow the assessment of methodological quality [10]. The study scored the maximum 5 points on the Jadad scale.

Study findings

The peer reviewed RCT [10] reported that in children with gastroenteritis treated with Plasma-Lyte had statistically significant greater increases in serum bicarbonate from baseline than did the 0.9 % NaCl group. Both treatment groups received similar fluid volumes. The Plasma-Lyte group had a significantly better dehydration scores at hour 2 and a non-significant better score at hour 4. No patient experienced clinically relevant worsening of laboratory findings or physical examination, and hospital admission rates were similar. One patient in each treatment group developed hypoketemia.

Four patients developed hyperkalemia, 1 with Plasma-Lyte and 3 with 0.9 % NaCl.

The non-peer reviewed RCT [14] reported statistically significantly higher mean pH in children treated with Plasma-Lyte. Variation in serum chloride, pH and base excess were all significantly greater in those treated with 0.9% NaCl.

In a before and after study children receiving 0.9% NaCl boluses, as resuscitation fluid, tended to have a higher maximum chloride, higher average chloride, lower pH and higher percentage creatinine increase than those given Plasma-Lyte [16]. Subgroup analysis showed a statistically significant difference in average serum chloride for children give 61–90 ml/kg total resuscitation volume [difference: −6.21, 95% confidence interval (CI)−9.55,−2.87]. Children who received Plasma-Lyte tended to have a higher pH than those receiving 0.9% NaCl. A statistically significant difference was seen in the children given 10–30 ml/kg total resuscitation volume [Plasma-Lyte 7.42 ± 0.49 vs 0.9% NaCl 7.33 ± 0.65; difference: 0.0913 (95% CI: –0.18 to −0.02)]. Significant differences were not seen in the clinical outcomes of length of stay or ventilation.

The conference abstracts for the two remaining studies [13-15] provided no statistical tests to enable interpretation of the findings.

DISCUSSION

A systematic review using a sensitive search strategy will identify all relevant published research. It is therefore possible to conclude with certainty that published research comparing Plasma-Lyte with other intravenous fluids in the paediatric population is very limited. Two publications were based on data that was presented in other publications, leaving only 5 original datasets. Six of the 7 included publications were conference abstracts which will not have been subject to peer review. The only paper published in a peer reviewed journal was a high quality randomised controlled trial which demonstrated the superiority of Plasma-Lyte over normal saline in paediatric patients with gastroenteritis. Conference abstracts are not only limited by the absence of peer review but often contain insufficient information to make judgments on the validity of their findings, for example it is not clear if the subgroup analysis was based on apriori hypothesis or post hoc analysis [16]. These remaining studies provide low grade evidence which suggests that Plasma-Lyte is equivalent, or possibly superior in some clinical situations, to alternative intravenous fluids.

At current prices available to the NHS in Wales Plasma-Lyte costs less than 0.9% sodium chloride in 500 ml bags and for maintenance fluids has the potential for additional savings from both fluid costs and staff time if 1000 ml bags are used (Bluavee Patel, personal communication). The National Institute for Health and Care Excellence (NICE) guidance on intravenous fluid therapy in children and young people in hospital recommends glucose-free crystalloids that contain sodium in the range 131–154 mmol/litre for IV resuscitation, and isotonic crystalloids that contain sodium in the range 131–154 mmol/litre as initial IV fluids for routine maintenance [17]. As an isotonic crystalloid available with and without glucose that contains 140 mmol/litre of sodium [6,18], Plasma-Lyte meets the criteria in the NICE guidance for use in children and young people.

CONCLUSION

Plasma-Lyte is a licensed isotonic fluid that can be used as an intravenous fluid in children and infants. It conforms to the 2015 NICE guideline on intravenous fluid therapy in children and young people in hospital [19]. The limited published evidence available for children suggests that, as in adult clinical trials, Plasma-Lyte is equivalent to or possibly superior in some situations to alternative intravenous fluids. Further clinical trials in children are urgently required.
### TABLE 1
Summary of included studies of Plasma-Lyte for intravenous fluid replacement or resuscitation as an alternative to other intravenous fluids in paediatric patients

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Design</th>
<th>Number of patients</th>
<th>Country</th>
<th>Disease / Setting</th>
<th>Study Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allen et al. [11]</td>
<td>Double blind Randomised Controlled Trial. Intervention Plasma-Lyte A (PLA) or 0.9 % sodium chloride (NaCl) for intravenous fluid replacement. aged &gt;=6 months to &lt;11 years. Primary outcome measure was serum bicarbonate levels at 4 h. Secondary outcomes included safety years, and tolerability.</td>
<td>US and Canada.</td>
<td>Dehydration secondary to acute gastroenteritis / paediatric emergency departments.</td>
<td>At hour 4, the PLA group had greater increases in serum bicarbonate from baseline than the 0.9 % NaCl group (mean +/- SD at 4 h: 18 +/- 3.74 vs 18.0 +/- 3.67); change from baseline of 1.6 and 0.0, respectively; P=0.004. Both treatment groups received similar fluid volumes. The PLA group had less abdominal pain and better dehydration scores at hour 2 (both P=0.03) but not at hour 4 (P=0.15 and 0.08, respectively). One patient in each treatment group developed hyponatremia. Four patients developed hyperkalaemia (PLA:1, 0.9 % NaCl:3).</td>
<td></td>
</tr>
<tr>
<td>Lima et al. [13]</td>
<td>Randomised controlled trial.Intervention NaCl 0.9% (NSG) or Plasma-Lyte (PLA) from anesthetic induction until 24 hours after surgery. Outcomes electrolytes and arterial blood gas analysis at three distinct moments: anesthetic induction, immediate postoperative day and first postoperative day.</td>
<td>Brazil</td>
<td>Elective neurosurgery for resection of brain tumour / Inpatient.</td>
<td>There was no significant variation of serum sodium on both groups and the values were kept within normal range. Serum chloride variation was significantly greater on NSG than PLA (6.57 +/- 3.42 vs 1.33 +/- 2.42, p=0.037), as well as pH (0.13 +/- 0.08 vs -0.06 +/- 0.095, p=0.02) and base excess variations (-4.98 +/- 3.12 vs -0.86 +/- 2.53, p=0.018). Mean pH was significantly lower on NSG (7.25 vs 7.38, p&lt;0.01).</td>
<td></td>
</tr>
<tr>
<td>Sutherland et al. [14]</td>
<td>Retrospective before and after study Change from traditional maintenance fluid (0.9% sodium chloride with 5% glucose or 0.45% sodium chloride with 5% glucose) to a new formulation (Plasmalyte-148 Glucose 5%). Retrospective audit in a Paediatric Intensive Care Unit (PICU) comparing 2010-2011 and 2011-2012 examining population serum electrolytes.</td>
<td>UK</td>
<td>Critically ill children / Paediatric Intensive Care Unit</td>
<td>Serum electrolytes showed no significant change between the two periods: Sodium: 141 mmol/l (2010-2011; range 95-187, median 140) to 143 mmol/l (2011-2012; range 126-190, median 141) Potassium: 3.99 mmol/l (2010-11; range 1.9-9.2, median 3.9) to 3.81 mmol/l (2011-2012; range 1.9-9.0, median 3.7) Chloride: 106 mmol/l (2010-11; range 70-141, median 105) to 106 mmol/l (2011-12; range 68-141, median 105).</td>
<td></td>
</tr>
<tr>
<td>Sutherland et al. [15]</td>
<td>Retrospective before and after study</td>
<td>UK</td>
<td>Critically ill children / Paediatric Intensive Care Unit</td>
<td>Conference abstract presenting same but abridged data from above conference abstract [13].</td>
<td></td>
</tr>
<tr>
<td>Kara et al. [16]</td>
<td>Retrospective cohort study Comparison outcomes of children who received plasmalyte during renal transplantation to those who received primarily normal saline.</td>
<td>New Zealand</td>
<td>Renal Transplantation / Inpatient</td>
<td>The first post-operative potassium checked on arrival in intensive care was 4.2 mmol/l (range 3.2-5.8) in the plasmalyte group and 4.6 (range 4.2-5.3) in the saline group. The chloride at 24 hours was on average 102 mmol/l (range 99-105) in the plasmalyte group, and 114 (range 112-116) in the saline group.</td>
<td></td>
</tr>
</tbody>
</table>
Retrospective before and after study. All children admitted in the 18-month periods before and after the change from 0.9% NaCl to Plasma-Lyte, and receiving a fluid bolus in the first 24 hours of admission. Arterial blood gas and creatinine values were up to 5 days after bolus fluid administration were examined. Patients 126 Children were stratified according to the total resuscitation volume (ml/kg). The primary outcome was plasma chloride. Secondary outcomes included blood pH and percentage change in creatinine. Clinical outcomes were length of ventilation and length of PICU stay.

Children receiving 0.9% NaCl boluses tended to have a higher maximum chloride, higher average chloride, lower pH and higher percentage creatinine increase than those given Plasma-Lyte. Subgroup analysis showed a statistically significant difference in average serum chloride for children given 61–90 ml/kg total resuscitation volume (Plasma-Lyte 105.59 ± 1.29 vs 0.9% NaCl 111.29 ± 2.1 mmol/L; difference: −6.21 [95% confidence interval (CI)−9.55,−2.87]). Patients who received Plasma-Lyte tended to have a higher pH than those receiving 0.9% NaCl. A statistically significant difference was seen in children given 10–30 ml/kg total resuscitation volume (Plasma-Lyte 7.42 ± 0.49 vs 0.9% NaCl 7.33 ± 0.65; difference: 0.0913 [95% CI: 0.18 to 0.02]). Significant differences were not seen in the clinical outcomes of length of stay or ventilation.

CONFLICT OF INTEREST
There are no conflicts of interest to disclose from all authors.

REFERENCES

Andrew et al. [17]